Our research program applies protein engineering technologies to develop physiological molecular targeting agents for molecular diagnostics and targeted therapy, with a focus on oncology and infectious disease. We balance (1) fundamental study of molecular evolution and protein biophysics, which empowers our protein engineering efforts; and (2) application of these advances to develop non-invasive diagnostics and therapeutics for clinical challenges in oncology and infectious disease. Our research is highly interdisciplinary including scientists, engineers, and collaborators across Chemical Engineering and Materials Science, Biomedical Engineering, Pharmacology, Chemistry, Oncology, Physiology, Medicinal Chemistry, Radiology, and more. We appreciate the support of the National Institutes of Health, the American Cancer Society, the University of Minnesota, and biotechnology partners.
Kim, M., Vala, M., Ertsgaard, C.T., Oh, S., Lodge, T.P., Bates, F.S., Hackel, B.J., "Surface Plasmon Resonance Study of the Binding of PEO-PPO-PEO Triblock Copolymer and PEO Homopolymer to Supported Lipid Bilayers" Langmuir. 2018 34: 6703-6712.
Case, B.A., Kruziki, M.A., Johnson, S.M., and Hackel, B.J., "Engineered charge redistribution of Gp2 proteins through guided diversity for improved PET imaging of epidermal growth factor receptor" Bioconj. Chem. 2018 29: 1646-1658.
Csizmar C.M., Petersburg J. Hendricks A., Stern L.A., Hackel B.J., and Wagner CR, "Engineering reversible cell-cell interactions with lipid anchored prosthetic receptors" Bioconj. Chem. 2018 29: 1291-1301.